Quick Facts

• Target Condition 1: Mild nervous tension
• Target Condition 2: Temporary difficulty falling asleep
• Therapeutic Goal: To support relaxation and sleep onset

---

What Валдисперт Treats: Main Uses and Benefits

Валдисперт is a preparation formulated for the temporary management of two common, self-limiting conditions. The primary therapeutic use is to provide relief for instances of mild nervous tension.

In addition to supporting the mitigation of mild daily stress, it is also indicated for use when a patient experiences difficulty falling asleep.

This medication is used in an effort to promote the onset of sleep. For both of these conditions, the overall goal of the treatment is to support the body's natural resting state and facilitate a sense of calmness.

It is important to note that the product is a widely available herbal medicinal product, and its primary indications are limited to these temporary and mild forms of distress. Treatment with Валдисперт may be considered among the options for appropriate patients seeking to alleviate these symptoms. Patients should always consult a physician for persistent or severe symptoms.

Eligibility for Валдисперт: Official Regulatory Information

The eligibility profile for Валдисперт, a medicinal product containing Valerian root, is formally defined by official regulatory documentation and restricts use to specific populations.

Populations Allowed and Excluded

Classification	Eligible Populations
Use Allowed	Adults and adolescents aged 12 years and older.
Use Not Recommended	Children under 12 years of age, pregnant women, and breastfeeding women.
Use Contraindicated	Individuals with known hypersensitivity or allergy to the active substance (Valerian root) or any excipients.

Key Regulatory Restrictions

Official labeling specifically states that use is not recommended in children under 12 years of age due to insufficient data to establish safety and efficacy in this age group. Similarly, use during pregnancy and lactation is not recommended as a precautionary measure, due to a lack of established safety data concerning the effects on the unborn child or infant.

Special Considerations

Patients with known allergies to the product's components are strictly contraindicated from use. For liquid formulations containing alcohol, individuals with conditions such as alcoholism, liver problems, or epilepsy are advised to consult a healthcare professional before use. This structure ensures that only populations with established regulatory consent or sufficient safety information are eligible to use the medicine.

Interaction Scope

Property	Details (Based Strictly on Regulatory Documentation)
Medicinal product categories with documented interactions:	Synthetic Sedatives and Hypnotics, CNS Depressants, Alcohol-Containing Products, Other Sedating Herbal Products, Substrates of CYP3A4.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic (PD) Potentiation, Additive Sedative Effects, Excipient-Related Caution (Alcohol).
Population-specific interaction notes (if applicable):	Caution for patients with Liver Disease or Epilepsy due to the alcohol content in the liquid tincture formulation.

Interaction Classifications (High-Level)

Property	Classification (Based Strictly on Regulatory Documentation)
Interaction severity classification (as defined in official documents):	No formal Contraindicated Combinations are documented. Restrictions are classified as "Avoid" or "Not Recommended."
Interaction-context constraints (as defined in official documents):	High-risk population caution is conditional on the pharmaceutical form (liquid tincture).

Resulting Interaction Structure

Official Interaction Statements:

• Co-administration with other CNS depressants, including synthetic sedatives and hypnotics, results in a pharmacodynamic interaction where additive sedative effects cannot be excluded. This combination is not recommended as a general precaution.
• The product's sedative outcome may be potentiated by alcohol (ethanol), requiring that excessive consumption of alcohol should be avoided.
• Official labeling notes that no clinically relevant interactions have been observed with drugs metabolized by the major hepatic cytochrome P450 enzymes (CYP 1A2, 2D6, 2E1, and 3A4/5).
• Potential for additive effects is documented when co-administered with other sedating herbal products (e.g., Hops or Melatonin).
• The alcohol content in the liquid formulation must be considered for patients with liver disease or epilepsy.
• The metabolic clearance of certain CYP3A4 substrates may be decreased, which could potentially increase the systemic exposure of the co-administered drug.

Connection to the Overall Interaction Profile

The regulatory profile defines the interaction structure primarily around the principle of pharmacodynamic potentiation, explicitly documenting the risks of additive sedation with other central nervous system depressants and with alcohol. The official documents clarify the lack of observed clinical relevance for common CYP-mediated pharmacokinetic interactions, and include specific excipient-related constraints for high-risk patient groups using the liquid form.

How Валдисперт Works

Валдисперт acts through molecular and cellular pathways to influence specific physiological processes. Its action is centered around distinct mechanistic domains, influencing receptor- and enzyme-mediated signaling to alter activity levels within targeted biological systems.

Modulation of Receptor-Mediated Signaling

This domain covers Валдисперт's primary interaction with specific cell-surface receptors, where it acts as either an agonist or antagonist to control the initial step of signal transduction. By initiating or blocking these early molecular steps, the drug modifies signaling sequences, which affects the rate of specific physiological signaling events driven by neurotransmitter or mediator activity.

Inhibition of Key Enzyme Activity

Валдисперт engages mechanisms that regulate metabolic or regulatory enzymes crucial for the biosynthesis or breakdown of certain mediators. Targeting these enzymes allows for the strategic adjustment of overall pathway activity. This results in the suppression of subsequent cascades and modulates the activity of specific molecular mediators, resulting in an altered pattern of pathway activity within the affected systems.

How to use Валдисперт: Official Administration Guidelines

Administration of this valerian root-based herbal medicinal product must adhere to the specified dosing instructions.

Official Dosing and Route

The product is administered orally as a coated tablet, which must be swallowed whole without chewing, with a liquid such as water. The maximum daily dose must not be exceeded, and the medicine is not recommended for children under 12 years of age.

Intended Use	Dosage and Frequency	Timing	Age-Group
Relief of Mild Nervousness	1 to 3 tablets per day	Distributed across the day	Adults and adolescents over 12 years
Relief of Sleep Disturbances	1 to 3 tablets	Half an hour before bedtime	Adults and adolescents over 12 years

For sleep disturbances, guidelines may include taking 2 tablets initially, with the option of an additional tablet in the evening if necessary, not to exceed a total of 4 tablets daily for some high-dose formulations.

Procedural and Timing Instructions

The onset of the full effect of valerian root extract is gradual; therefore, use is not suitable for acute (immediate) treatment of nervousness or insomnia. A continuous treatment duration of 2 to 4 weeks is typically recommended to achieve the expected benefit. If symptoms persist or worsen after two weeks of continuous use, consultation with a healthcare professional is explicitly advised. Administration in relation to meals is generally not specified, but for some formulations, taking tablets after meals is instructed.

Валдисперт: Recent Clinical Evidence

Evidence for Use in Temporary Difficulty Falling Asleep

Research has explored Valerian root extract in the context of mild sleep disturbances, mainly in Randomized Controlled Trials (RCTs). These trials research examined how people with self-reported sleep issues experienced changes over time, exploring outcomes like sleep latency and patient-reported discomfort related to sleep quality. Study populations primarily involved adults who described themselves as "poor sleepers" or geriatric patients with mild, age-related sleep challenges.

When examining the available evidence, findings describe patterns observed in the studies that sometimes included positive measurements in self-reported sleep quality. However, the research highlights changes measured during the study period and shows that findings varied across different trials. This variability is often due to the research evidence quality varies across studies, sometimes using different extract preparations or doses.

Evidence for Use in Mild Nervous Tension and Restlessness

Valerian root extract was evaluated in the context of conditions characterized by fluctuating or episodic manifestations, such as mild nervous tension and restlessness. Studies explored outcomes monitoring physiological strain or stress, using standardized scales to evaluate reported anxiety and emotional excitability levels in adults. This use is also supported by evidence from a long history of use in traditional practice.

What is Still Uncertain About Валдисперт’s Research

Several limitations exist in the current body of research. The evidence for both indications has primarily focused on short-term use, meaning long-term effects are not fully established, and limited data are available for outcomes beyond a few weeks. Evidence quality varies across studies, and a key gap is the reliance on subjective, patient-reported outcomes rather than objective clinical or physiological markers, particularly in the older studies. Research provides context but not individual predictions regarding responses.

Common questions about Валдисперт (FAQ)

Q: What is Валдисперт?

Валдисперт is the trade name for the medication Valsartan in some countries. Valsartan belongs to a class of drugs called Angiotensin II Receptor Blockers (ARBs). It is primarily used to treat high blood pressure (hypertension) and heart failure. It may also be used to improve survival after a heart attack in certain patients.

---

Q: How does Valsartan work to treat high blood pressure?

Valsartan works by blocking the effects of a substance in the body called Angiotensin II. Angiotensin II causes blood vessels to narrow, which raises blood pressure. By blocking its action, Valsartan helps to relax and widen blood vessels, which allows blood to flow more easily and thus lowers blood pressure.

---

Q: What are the common side effects of Valsartan?

Common side effects of Valsartan may include:

• Dizziness or lightheadedness (especially when standing up)
• Headache
• Tiredness or fatigue
• Diarrhea
• Joint and back pain

Most people tolerate Valsartan well, and these side effects are often mild and temporary. If side effects persist or are severe, a healthcare provider should be consulted.

---

Q: Who should not take Valsartan?

Valsartan should not be taken by individuals who:

• Are pregnant or planning to become pregnant, as it can harm the fetus.
• Have a known allergy or severe hypersensitivity to Valsartan or any of its ingredients.
• Are taking an anti-hypertensive drug containing aliskiren (especially in patients with diabetes or moderate to severe kidney problems).
• Have a severe liver condition (e.g., biliary cirrhosis).

It is essential to discuss your complete medical history with your healthcare provider before starting treatment.

---

Q: Can Valsartan interact with other medications?

Yes, Valsartan can interact with several other medications, which may alter its effects or increase the risk of side effects. Notable interactions include:

• Potassium-sparing diuretics or potassium supplements, which can lead to dangerously high potassium levels (hyperkalemia).
• Nonsteroidal anti-inflammatory drugs (NSAIDs), which may reduce the blood-pressure-lowering effect and increase the risk of kidney problems.
• Lithium, as Valsartan can increase the concentration of Lithium in the blood, leading to toxicity.

Always provide your doctor or pharmacist with a complete list of all medications, supplements, and herbal products you are currently taking.

Official Storage and Disposal Requirements

Storage and disposal instructions for Valdispert Oral Solution are defined in official government regulatory documents to maintain product quality and ensure safety.

---

Storage Conditions

Requirement	Specific Instruction
Temperature	Do not store above 30°C.
Stability	Do not use the medicine after the expiration date printed on the package.
Child Safety	Keep Valdispert out of the reach and sight of children.

---

Proper Disposal

Unused or expired Valdispert must be disposed of correctly to protect the environment. The regulatory guidance states that this medicine must not be discarded through household waste or poured into wastewater. Instead, all unused medicine and packaging should be taken to an authorized pharmacy collection point (such as a SIGRE point).